Previous findings that high JAM-A and HER2 are associated with poor prognosis in breast cancer patients [3,7,8] were supported in two different ways: (1) by revealing via an online survival tool [38] that high co-expression of JAM-A and HER2 mRNA associate with poor survival outcomes in breast cancer patients, and (2) by providing data that expressional changes in JAM-A induce parallel changes in HER2 expression in breast cancer cell lines. This evidence concerns the gene F11R and breast carcinoma.